Neuroscience Today—July 1, 2026

LucidQuest

2 hours ago

This week’s Neuroscience update highlights regulatory progress, clinical trial advances, pipeline expansion, reimbursement developments, and emerging data across neurological disorders.

In Today’s Newsletter

Dive deeper

🧬 Cemdisiran FDA and EMA review for gMG [1] [US, EU • 22 Jun 2026]

https://newsroom.regeneron.com/news-releases/news-release-details/cemdisiran-regulatory-submissions-accepted-review-fda-and-ema
Context: Regeneron’s Phase 3 NIMBLE trial evaluated subcutaneous cemdisiran every 12 weeks in symptomatic adult anti-AChR-positive gMG.
Key point: FDA accepted the NDA under Priority Review, with a Nov 2026 target action date, and EMA accepted the European application.
Implication: May influence prescriber choice and payer reviews pending full data.

🛡️ IMAAVY gMG data at EAN 2026 [2] [Switzerland • 26 Jun 2026]

https://www.jnj.com/media-center/press-releases/johnson-johnson-presents-new-imaavy-nipocalimab-aahu-data-at-european-academy-of-neurology-ean-2026-congress-reinforcing-sustained-disease-control-in-generalized-myasthenia-gravis
Context: Johnson & Johnson presented 12 abstracts at EAN 2026, including Vivacity-MG3 post-hoc analyses and PETUNIA pregnancy-outcomes study design.
Key point: IMAAVY (nipocalimab-aahu) analyses supported sustained disease control in antibody-positive gMG subgroups.
Implication: May influence prescriber choice and payer reviews pending full data.

🧠 Centanafadine Phase 3b ADHD-anxiety topline [3] [US • 25 Jun 2026]

https://www.otsuka.co.jp/en/company/newsreleases/2026/20260625_1.html
Context: Otsuka studied centanafadine XR 280 mg once daily in adults with ADHD and comorbid anxiety over 8 weeks.
Key point: The Phase 3b trial met its primary endpoint on AISRS total score and showed improvement on HAM-A at week 8.
Implication: May influence prescriber choice and payer reviews pending full data.

🔬 PTD802 FDA IND clearance in multiple sclerosis [4] [US • 22 Jun 2026]

https://phenotherapeutics.com/pheno-therapeutics-granted-fda-ind-clearance-for-lead-multiple-sclerosis-therapeutic-candidate-ptd802/
Context: Pheno Therapeutics’ PTD802 is a selective GPR17 antagonist designed to promote remyelination in neurological diseases such as MS.
Key point: FDA cleared the IND, enabling a first-in-human US study of PTD802 in healthy volunteers.
Implication: Signals pipeline investment and modality expansion.

🧪 NEO100 UAE IND approval in high-grade glioma [5] [UAE • 23 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/23/3316012/0/en/neonc-technologies-receives-uae-ind-approval-for-neo100-expanding-global-development-ahead-of-anticipated-phase-2-data-milestone.html
Context: NeOnc’s NEO100 is an intranasal purified perillyl alcohol formulation for progressive or recurrent Grade III or IV gliomas.
Key point: UAE IND authorization covers three NEO100 protocols across adult Phase 1–2 studies and pediatric pathways.
Implication: Signals pipeline investment and modality expansion.

🧫 CNSide gains Elevance Health national coverage [6] [US • 25 Jun 2026]

https://www.globenewswire.com/news-release/2026/06/25/3317434/0/en/plus-therapeutics-secures-national-coverage-agreement-with-elevance-health-for-cnside-cerebrospinal-fluid-assay-for-metastatic-cns-cancer.html
Context: Plus Therapeutics’ CNSide CSF assay platform supports diagnosis, treatment monitoring, and treatment guidance in leptomeningeal metastases.
Key point: Elevance Health coverage became effective 01 May 2026, adding about 45.4 million covered lives and bringing total contracted coverage to 126 million.
Implication: May expand screening, initiation, and follow-up at scale.

⏳ Relutrigine PDUFA extended to Dec 2026 [7] [US • 29 Jun 2026]

https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-extension-period
Context: Praxis is seeking FDA review of relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies.
Key point: FDA extended the NDA review by three months, setting a new PDUFA target action date of 27 Dec 2026.
Implication: May influence prescriber choice and payer reviews pending full data.

🧠 Solriamfetol FOCUS-3 starts in adolescent ADHD [8] [US • 26 Jun 2026]

https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-initiates-focus-3-phase-3-trial-solriamfetol
Context: Axsome’s FOCUS-3 is a randomized, double-blind, placebo-controlled Phase 3 trial in adolescents aged 12 to under 18 years with ADHD.
Key point: The first patient was dosed; the trial will assess solriamfetol versus placebo over 6 weeks using ADHD-RS-5 total score.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

gMG competition continues to widen across complement inhibition and FcRn blockade, with cemdisiran and IMAAVY adding differentiated evidence packages. [1], [2]
ADHD development activity is broadening across adult comorbid anxiety and adolescent populations. [3], [8]
CNS pipelines are advancing across remyelination, glioma delivery, and epilepsy precision-medicine indications. [4], [5], [7]
Coverage expansion for CNSide may affect diagnostic access and treatment monitoring in metastatic CNS cancer. [6]

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Neuroscience archive on our research hub page.

FAQ

What is cemdisiran (Regeneron) being reviewed for?

Cemdisiran is under FDA and EMA review for adult anti-AChR-positive generalized myasthenia gravis. FDA Priority Review has a Nov 2026 target action date. [1]

What did Johnson & Johnson report for IMAAVY (nipocalimab-aahu)?

J&J reported EAN 2026 analyses from Vivacity-MG3 and related evidence generation in antibody-positive gMG, including early disease, lower symptom burden, infection-period outcomes, and pregnancy-data plans. [2]

What did Otsuka report for centanafadine XR?

Otsuka said centanafadine XR met the primary endpoint in adults with ADHD and comorbid anxiety, with full results planned for a future scientific meeting. [3]

What is PTD802 (Pheno Therapeutics)?

PTD802 is a selective GPR17 antagonist designed to promote remyelination. FDA IND clearance enables a first-in-human study in healthy volunteers. [4]

What does the NEO100 UAE IND approval cover?

The UAE authorization covers NeOnc’s NEO100-01, NEO100-02, and NEO100-03 protocols across adult Phase 1–2 studies, plus pediatric pathways pending further protocol review. [5]

What changed for Praxis’ relutrigine FDA review?

FDA extended the NDA review period by three months after additional sensitivity analyses were deemed a major amendment. The updated PDUFA date is 27 Dec 2026. [7]

Entities / Keywords

Cemdisiran, Regeneron, Alnylam, generalized myasthenia gravis, gMG, anti-AChR-positive, complement C5, siRNA, NIMBLE
IMAAVY, nipocalimab-aahu, Johnson & Johnson, J&J, FcRn blocker, Vivacity-MG3, PETUNIA, EAN 2026
Centanafadine XR, Otsuka, OPDC, ADHD, comorbid anxiety, AISRS, HAM-A, NDSRI
PTD802, Pheno Therapeutics, GPR17 antagonist, remyelination, multiple sclerosis, MS, FDA IND
NEO100, NeOnc Technologies, perillyl alcohol, intranasal delivery, glioma, CNS cancer, UAE IND
CNSide, Plus Therapeutics, CNSide Diagnostics, Elevance Health, CSF assay, leptomeningeal metastases
Relutrigine, Praxis Precision Medicines, SCN2A, SCN8A, DEE, PDUFA, FDA NDA
Solriamfetol, Axsome Therapeutics, FOCUS-3, ADHD-RS-5, adolescent ADHD